Global Asthma Disease Market – Industry Trends and Forecast to 2030

Asthma Disease Market Analysis and Size

According to the global asthma report, an estimated 339 million people worldwide have asthma. It is one of the most common chronic diseases globally. The incidence of asthma can be influenced by factors such as genetics, environmental exposures (such as allergens and pollutants), socio-economic status, and healthcare access. However, the burden of asthma in low- and middle-income countries is increasing due to various factors such as urbanization, changing lifestyles, and exposure to environmental triggers.

Data Bridge Market Research analyses that the asthma disease market which was USD 24,847.56 million in 2022, would rocket up to USD 34,798.31 million by 2030, and is expected to undergo a CAGR of 4.3% during the forecast period. This indicates the market value. “Quick-relief (rescue) Medications” dominates the duration of action type segment of the asthma disease market owing to the growing demand for better methods for treatment in asthma patients. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Asthma Disease Market Scope and Segmentation

Market Definition

Asthma is a respiratory disease that results in narrowing the airways which leads to difficulty in breathing. Asthma leads to excessive development of mucous in the windpipe which results in period but repetitive attack of breathlessness. Asthma also brings along chest pain, coughing and congestion. Asthma results in lung inflammation and tightens the muscles.

Global Asthma Disease Market Dynamics

Drivers

• Increasing Prevalence of Asthma Disease

The rising prevalence of asthma worldwide is a significant driver of the asthma disease market. Factors such as environmental pollution, urbanization, and changes in lifestyle contribute to the increasing incidence of asthma

• Growing Awareness and Diagnosis

Increasing awareness about asthma and its symptoms has led to improved diagnosis rates. This in turn, drives the demand for asthma treatments and medications

• Government Initiatives and Healthcare Policies

Government initiatives focused on improving asthma management, providing better access to healthcare, and raising awareness about asthma contribute to the growth of the market. Healthcare policies that support affordable and accessible asthma treatments also drive market expansion

• Increasing Healthcare Expenditure

The rise in healthcare expenditure, particularly in developing countries, supports the growth of the asthma disease market. Increased spending on healthcare infrastructure, research and development, and access to medications positively impacts market growth

Opportunities

• Rising Focus on Pediatric Asthma

Pediatric asthma is a significant market opportunity, as the prevalence of asthma in children continues to rise. There is a need for age-appropriate asthma medications, devices, and management strategies to address the unique challenges faced by children with asthma

• Technological Advancements in Inhaler Devices

Inhaler devices play a crucial role in asthma management. Advancements in inhaler technology, such as smart inhalers and digital health solutions, present opportunities for improved medication adherence, monitoring, and patient engagement

Restraints/Challenges

• High Cost of Treatment

The cost of asthma medications, particularly newer biologics and targeted therapies, can be high. This can limit access to these treatments, especially in developing countries or for individuals without adequate insurance coverage. Affordability remains a significant challenge in the asthma disease market

• Lack of Awareness and Under Diagnosis

Despite efforts to raise awareness about asthma, there is still a significant proportion of undiagnosed or underdiagnosed cases. Lack of awareness among patients and healthcare providers can lead to delayed diagnosis and inadequate management of asthma

• Limited Treatment Options for Severe Asthma

While advancements have been made in the treatment of asthma, there is still a need for more effective and targeted therapies, especially for individuals with severe asthma. Limited treatment options for severe asthma pose a challenge in achieving optimal asthma control for these patients

• Regulatory and Reimbursement Challenges

Regulatory requirements and reimbursement policies can pose challenges for market players. Obtaining regulatory approvals and reimbursement coverage for asthma medications and devices can be time-consuming and costly, impacting market entry and adoption

This asthma disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the asthma disease market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth

Recent Developments

• In May 2021, AstraZeneca announced positive results from their Phase III ETHOS trial evaluating their biologic therapy, tezepelumab, in patients with severe, uncontrolled asthma. The trial showed that tezepelumab significantly reduced asthma exacerbations and improved lung function compared to standard of care
• In April 2021, GSK announced that their biologic therapy, mepolizumab, received FDA approval for use in children aged 6 to 11 with severe eosinophilic asthma. This expanded the indication for mepolizumab, which was previously approved for use in patients aged 12 and older

Global Asthma Disease Market Scope

The asthma disease market is segmented on the basis of classification type, duration of action type, route of administration and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Classification Type

• Mild Intermittent Asthma
• Mild Persistent Asthma
• Moderate Persistent Asthma
• Severe Persistent Asthma

Duration of Action Type

• Long-Term Asthma Control Medications
• Inhaled Corticosteroids
• Beclomethasone Dipropionate
• Omalizumab
• Fluticasone Furoate Inhalation Powder
• Prednisone Delayed-Release Tablets
• Mometasone Furoate
• Formoterol Fumarate Dehydrate
• Anticholinergics
• Tiotropium Bromide
• Leukotriene Modifiers
• Reslizumab
• Mepolizumab
• Montelukast.
• Long-Acting Beta Agonists
• Salmeterol
• Formoterol
• Arformoterol
• Theophylline
• Quick-relief (rescue) Medications
• Short Acting Beta Agonists
• Albuterol sulphate
• Salbutamol
• Allergy Medications
• Allergy Shots (Immunotherapy)
• Omalizumab (Xolair)
• Others

Route of Administration

• Oral
• Inhaled
• Intravenous
• Others

End-Users

• Hospitals
• Homecare
• Specialty Clinics 
• Others

Global Asthma Disease Market Regional Analysis/Insights

The global asthma disease market is analysed and market size insights and trends are provided by classification type, duration of action type, route of administration and end users as referenced above.

The countries covered in the asthma disease market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa.

North America dominates the asthma disease market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having respiratory diseases specifically asthma.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for diagnosis and treatment procedures, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Asthma Disease Market Share Analysis

The asthma disease market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the company’s focus related to the asthma disease market.

Some of the major players operating in the asthma disease market are:

• Merck & Co., Inc. (U.S.)
• Sanofi (France)
• Novartis AG (Switzerland)
• Astellas Pharma Inc. (Japan)
• Pfizer Inc. (U.S.)
• Abbott (U.S.)
• Eli Lilly and Company (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Takeda Pharmaceutical Company Limited. (Japan)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Boehringer Ingelheim International GmbH (Germany)
• Mylan N.V (U.S.)
• GlaxoSmithKline plc (U.K.)
• Regeneron Pharmaceuticals Inc (U.S.)
• AstraZeneca (U.K.)
• AbbVie Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Vectura Group plc (U.K.)
• Sunovion Pharmaceuticals Inc. (U.S.)
• Alkermes (Ireland)

SKU-37136